[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 15 of about 15
1. Dreyer ZE, Kadota RP, Stewart CF, Friedman HS, Mahoney DH, Kun LE, McCluggage CW, Burger PC, Kepner J, Heideman RL, Pediatric Oncology Group: Phase 2 study of idarubicin in pediatric brain tumors: Pediatric Oncology Group study POG 9237. Neuro Oncol; 2003 Oct;5(4):261-7
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phase 2 study of idarubicin in pediatric brain tumors: Pediatric Oncology Group study POG 9237.
  • In previous reports, the alcohol metabolite of IDA, 4-demethoxydaunorubicinol (idarubicinol, or IDOL), had cytotoxic activity and the ability to penetrate the blood-brain barrier.
  • For this reason, the Pediatric Oncology Group conducted a Phase 2 trial of IDA for children with recurrent or progressive brain tumors.
  • Patients were stratified by tumor types into 6 categories: stratum 1, low-grade astrocytoma; stratum 2, malignant glioma (glioblastoma multiforme and anaplastic astrocytoma); stratum 3, medulloblastoma; stratum 4, brainstem glioma; stratum 5, ependymoma; and stratum 6, miscellaneous malignant tumors not included in the previous diagnoses.
  • The systemic clearance data for IDA and IDOL were nearly identical to those published on patients with leukemia, and the plasma elimination of the IDOL metabolite was substantially longer than that of the parent drug IDA.
  • We conclude from this data and from that in nonhuman primates that it is unlikely that IDA, daunomycin, or other related anthracyclines will be useful for treating primary CNS tumors.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Brain Neoplasms / drug therapy. Idarubicin / therapeutic use
  • [MeSH-minor] Adolescent. Adult. Child. Child, Preschool. Female. Humans. Infant. Male

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Childhood Brain Tumors.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 14565163.001).
  • [ISSN] 1522-8517
  • [Journal-full-title] Neuro-oncology
  • [ISO-abbreviation] Neuro-oncology
  • [Language] eng
  • [Publication-type] Clinical Trial; Clinical Trial, Phase II; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] ZRP63D75JW / Idarubicin
  • [Other-IDs] NLM/ PMC1920677
  •  go-up   go-down


2. Lashford LS, Thiesse P, Jouvet A, Jaspan T, Couanet D, Griffiths PD, Doz F, Ironside J, Robson K, Hobson R, Dugan M, Pearson AD, Vassal G, Frappaz D, United Kingdom Children's Cancer Study Group and French Society for Pediatric Oncology Intergroup Study: Temozolomide in malignant gliomas of childhood: a United Kingdom Children's Cancer Study Group and French Society for Pediatric Oncology Intergroup Study. J Clin Oncol; 2002 Dec 15;20(24):4684-91
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Temozolomide in malignant gliomas of childhood: a United Kingdom Children's Cancer Study Group and French Society for Pediatric Oncology Intergroup Study.
  • PURPOSE: To determine the response rate of the malignant gliomas of childhood to an oral, daily schedule of temozolomide.
  • PATIENTS AND METHODS: A multicenter, phase II evaluation of an oral, daily schedule of temozolomide (200 mg/m(2) on 5 consecutive days) was undertaken in children with relapsed or progressive, biopsy-proven, high-grade glioma (arm A) and progressive, diffuse, intrinsic brainstem glioma (arm B).
  • Evidence of activity was defined by radiologic evidence of a sustained reduction in tumor size on serial magnetic resonance imaging scans.
  • Stabilization of disease was also documented and was most noteworthy for brainstem gliomas, where two patients achieved both radiologic static disease and discontinued steroid medication.
  • CONCLUSION: Despite moderate toxicity, objective response rates to temozolomide have been low, indicating that temozolomide has minimal activity in the high-grade gliomas of childhood.
  • [MeSH-major] Antineoplastic Agents, Alkylating / therapeutic use. Brain Neoplasms / drug therapy. Dacarbazine / analogs & derivatives. Dacarbazine / therapeutic use. Glioma / drug therapy
  • [MeSH-minor] Adolescent. Bone Marrow / drug effects. Child. Child, Preschool. Female. Humans. Male. Thrombocytopenia / chemically induced

  • Genetic Alliance. consumer health - Childhood Cancer.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Childhood Brain Tumors.
  • Hazardous Substances Data Bank. DACARBAZINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12488414.001).
  • [ISSN] 0732-183X
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Clinical Trial; Clinical Trial, Phase II; Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Alkylating; 7GR28W0FJI / Dacarbazine; 85622-93-1 / temozolomide
  •  go-up   go-down


3. Zarghooni M, Bartels U, Lee E, Buczkowicz P, Morrison A, Huang A, Bouffet E, Hawkins C: Whole-genome profiling of pediatric diffuse intrinsic pontine gliomas highlights platelet-derived growth factor receptor alpha and poly (ADP-ribose) polymerase as potential therapeutic targets. J Clin Oncol; 2010 Mar 10;28(8):1337-44
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Whole-genome profiling of pediatric diffuse intrinsic pontine gliomas highlights platelet-derived growth factor receptor alpha and poly (ADP-ribose) polymerase as potential therapeutic targets.
  • PURPOSE: Diffuse intrinsic pontine glioma (DIPG) is one of the most devastating of pediatric malignancies and one for which no effective therapy exists.
  • A major contributor to the failure of therapeutic trials is the assumption that biologic properties of brainstem tumors in children are identical to cerebral high-grade gliomas of adults.
  • A better understanding of the biology of DIPG itself is needed in order to develop agents targeted more specifically to these children's disease.
  • RESULTS: Analysis of DIPG copy number alterations showed recurrent changes distinct from those of pediatric supratentorial high-grade astrocytomas.
  • CONCLUSION: To our knowledge, our data provides the first, comprehensive high-resolution genomic analysis of pediatric DIPG.
  • [MeSH-major] Brain Stem Neoplasms / genetics. Glioma / genetics. Poly(ADP-ribose) Polymerases / genetics. Polymorphism, Single Nucleotide. Receptor, Platelet-Derived Growth Factor alpha / genetics
  • [MeSH-minor] Autopsy. Case-Control Studies. Child. Child, Preschool. DNA Repair / genetics. DNA, Neoplasm / analysis. Female. Gene Dosage. Humans. Infant. Infant, Newborn. Loss of Heterozygosity. Male. Oligonucleotide Array Sequence Analysis

  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20142589.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Grant] Canada / Canadian Institutes of Health Research / / MOP 82727
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / DNA, Neoplasm; EC 2.4.2.30 / PARP1 protein, human; EC 2.4.2.30 / Poly(ADP-ribose) Polymerases; EC 2.7.10.1 / Receptor, Platelet-Derived Growth Factor alpha
  •  go-up   go-down


Advertisement
4. Broniscer A, Leite CC, Lanchote VL, Machado TM, Cristófani LM: Radiation therapy and high-dose tamoxifen in the treatment of patients with diffuse brainstem gliomas: results of a Brazilian cooperative study. Brainstem Glioma Cooperative Group. J Clin Oncol; 2000 Mar;18(6):1246-53
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Radiation therapy and high-dose tamoxifen in the treatment of patients with diffuse brainstem gliomas: results of a Brazilian cooperative study. Brainstem Glioma Cooperative Group.
  • PURPOSE: The efficacy of radiation therapy (RT) combined with tamoxifen (TX) was tested in patients diagnosed with diffuse brainstem gliomas in a multicenter trial.
  • Based on our poor results, we recommend that alternative treatments be tested in patients with this type of tumor.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Brain Stem Neoplasms / drug therapy. Brain Stem Neoplasms / radiotherapy. Glioma / drug therapy. Glioma / radiotherapy. Tamoxifen / therapeutic use
  • [MeSH-minor] Adolescent. Child. Child, Preschool. Combined Modality Therapy. Drug Administration Schedule. Female. Humans. Infant. Male. Radiotherapy, High-Energy. Survival Analysis

  • Genetic Alliance. consumer health - Glioma.
  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. TAMOXIFEN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 10715294.001).
  • [ISSN] 0732-183X
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 094ZI81Y45 / Tamoxifen
  •  go-up   go-down


5. Pollack IF, Jakacki RI, Blaney SM, Hancock ML, Kieran MW, Phillips P, Kun LE, Friedman H, Packer R, Banerjee A, Geyer JR, Goldman S, Poussaint TY, Krasin MJ, Wang Y, Hayes M, Murgo A, Weiner S, Boyett JM: Phase I trial of imatinib in children with newly diagnosed brainstem and recurrent malignant gliomas: a Pediatric Brain Tumor Consortium report. Neuro Oncol; 2007 Apr;9(2):145-60
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phase I trial of imatinib in children with newly diagnosed brainstem and recurrent malignant gliomas: a Pediatric Brain Tumor Consortium report.
  • This study estimated the maximum tolerated dose (MTD) of imatinib with irradiation in children with newly diagnosed brainstem gliomas, and those with recurrent malignant intracranial gliomas, stratified according to use of enzyme-inducing anticonvulsant drugs (EIACDs).
  • In the brainstem glioma stratum, imatinib was initially administered twice daily during irradiation, but because of possible association with intratumoral hemorrhage (ITH) was subsequently started two weeks after irradiation.
  • Twenty-four evaluable patients received therapy before the amendment, and three of six with a brainstem tumor experienced dose-limiting toxicity (DLT): one had asymptomatic ITH, one had grade 4 neutropenia and, one had renal insufficiency.
  • None of 18 patients with recurrent glioma experienced DLT.
  • After protocol amendment, 3 of 16 patients with brainstem glioma and 2 of 11 patients with recurrent glioma who were not receiving EIACDs experienced ITH DLTs, with three patients being symptomatic.
  • The recommended phase II dose for brainstem gliomas was 265 mg/m(2).
  • Three of 27 patients with brainstem gliomas with imaging before and after irradiation, prior to receiving imatinib, had new hemorrhage, excluding their receiving imatinib.
  • In summary, recommended phase II imatinib doses were determined for children with newly diagnosed brainstem glioma and recurrent high-grade glioma who were not receiving EIACDs.
  • Imatinib may increase the risk of ITH, although the incidence of spontaneous hemorrhages in brainstem glioma is sufficiently high that this should be considered in studies of agents in which hemorrhage is a concern.

  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • Hazardous Substances Data Bank. IMATINIB MESYLATE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Int J Cancer. 2000 Feb 1;85(3):398-406 [10652433.001]
  • [Cites] Dig Dis Sci. 2005 Jan;50(1):65-9 [15712639.001]
  • [Cites] Cancer Res. 2000 Sep 15;60(18):5143-50 [11016641.001]
  • [Cites] N Engl J Med. 2001 Apr 5;344(14):1031-7 [11287972.001]
  • [Cites] N Engl J Med. 2001 Apr 5;344(14):1038-42 [11287973.001]
  • [Cites] N Engl J Med. 2001 Apr 5;344(14):1052-6 [11287975.001]
  • [Cites] Cancer Res. 2001 Apr 1;61(7):2929-34 [11306470.001]
  • [Cites] J Chromatogr B Analyt Technol Biomed Life Sci. 2002 Mar 5;768(2):325-40 [11888061.001]
  • [Cites] Cancer Res. 2002 Jul 1;62(13):3729-35 [12097282.001]
  • [Cites] J Clin Oncol. 2002 Aug 15;20(16):3431-7 [12177103.001]
  • [Cites] N Engl J Med. 2002 Aug 15;347(7):472-80 [12181401.001]
  • [Cites] N Engl J Med. 2002 Aug 15;347(7):481-7 [12181402.001]
  • [Cites] Cancer Res. 2003 Nov 1;63(21):7377-83 [14612536.001]
  • [Cites] J Clin Oncol. 2004 Mar 1;22(5):935-42 [14990650.001]
  • [Cites] Cancer. 2006 Mar 15;106(6):1364-71 [16463390.001]
  • [Cites] Cancer Chemother Pharmacol. 2004 Apr;53(4):313-23 [14658008.001]
  • [Cites] Blood. 2004 Nov 1;104(9):2655-60 [15231574.001]
  • [Cites] Cancer. 1988 Mar 1;61(5):896-902 [3338054.001]
  • [Cites] Cancer Lett. 1988 Jan;38(3):283-96 [3258178.001]
  • [Cites] J Neurooncol. 1990 Feb;8(1):1-12 [2156959.001]
  • [Cites] J Clin Invest. 1990 Jul;86(1):131-40 [2164040.001]
  • [Cites] Neuroradiology. 1990;32(4):265-71 [2234384.001]
  • [Cites] J Neurosurg. 1991 Aug;75(2):284-93 [1649272.001]
  • [Cites] J Biol Chem. 1991 Sep 5;266(25):16755-63 [1653246.001]
  • [Cites] Science. 1991 Nov 22;254(5035):1146-53 [1659742.001]
  • [Cites] Childs Nerv Syst. 1991 Dec;7(8):432-6 [1665101.001]
  • [Cites] Cancer Res. 1992 Jun 1;52(11):3213-9 [1317261.001]
  • [Cites] Cancer. 1993 Aug 15;72(4):1414-21 [8339232.001]
  • [Cites] J Cell Physiol. 1994 Feb;158(2):381-9 [8106574.001]
  • [Cites] Neurosurgery. 1993 Dec;33(6):1026-9; discussion 1029-30 [8133987.001]
  • [Cites] Neurosurgery. 1994 Feb;34(2):309-14; discussion 314-5 [8177392.001]
  • [Cites] Cancer Res. 1994 Dec 1;54(23):6106-14 [7954456.001]
  • [Cites] N Engl J Med. 1994 Dec 1;331(22):1500-7 [7969301.001]
  • [Cites] Stat Med. 1995 Jun 15;14(11):1149-61 [7667557.001]
  • [Cites] Nat Med. 1996 May;2(5):561-6 [8616716.001]
  • [Cites] J Clin Oncol. 1996 Sep;14(9):2495-503 [8823328.001]
  • [Cites] J Neurooncol. 1996 May-Jun;28(2-3):207-22 [8832463.001]
  • [Cites] Pediatr Neurosurg. 1996;24(4):185-92 [8873160.001]
  • [Cites] Eur J Cancer. 1996 Dec;32A(13):2236-41 [9038604.001]
  • [Cites] Surg Neurol. 1998 Feb;49(2):189-95; discussion 196 [9457270.001]
  • [Cites] Pediatr Neurosurg. 1998 Nov;29(5):228-44 [9917540.001]
  • [Cites] Cancer Res. 1999 Apr 1;59(7):1464-72 [10197615.001]
  • [Cites] Nature. 2000 Sep 14;407(6801):249-57 [11001068.001]
  • (PMID = 17293590.001).
  • [ISSN] 1522-8517
  • [Journal-full-title] Neuro-oncology
  • [ISO-abbreviation] Neuro-oncology
  • [Language] ENG
  • [Grant] United States / NCRR NIH HHS / RR / M01 RR000188; United States / NCI NIH HHS / CA / U01 CA081457; United States / NCRR NIH HHS / RR / M01 RR00188-37; United States / NCI NIH HHS / CA / U01 CA81457
  • [Publication-type] Clinical Trial, Phase I; Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Benzamides; 0 / Piperazines; 0 / Pyrimidines; 8A1O1M485B / Imatinib Mesylate
  • [Other-IDs] NLM/ PMC1871662
  •  go-up   go-down


6. Gururangan S, Chi SN, Young Poussaint T, Onar-Thomas A, Gilbertson RJ, Vajapeyam S, Friedman HS, Packer RJ, Rood BN, Boyett JM, Kun LE: Lack of efficacy of bevacizumab plus irinotecan in children with recurrent malignant glioma and diffuse brainstem glioma: a Pediatric Brain Tumor Consortium study. J Clin Oncol; 2010 Jun 20;28(18):3069-75
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Lack of efficacy of bevacizumab plus irinotecan in children with recurrent malignant glioma and diffuse brainstem glioma: a Pediatric Brain Tumor Consortium study.
  • PURPOSE: A phase II study of bevacizumab (BVZ) plus irinotecan (CPT-11) was conducted in children with recurrent malignant glioma (MG) and intrinsic brainstem glioma (BSG).
  • Correlative studies included diffusion weighted and T1 dynamic contrast-enhanced permeability imaging, BVZ pharmacokinetics, and estimation of vascular endothelial growth factor receptor 2 (VEGFR-2) phosphorylation in peripheral blood mononuclear cells (PBMC) after single-agent BVZ.
  • Toxicities related to BVZ included grade 1 to 3 fatigue in seven patients, grade 1 to 2 hypertension in seven patients, grade 1 CNS hemorrhage in four patients, and grade 4 CNS ischemia in two patients.
  • CONCLUSION: BVZ plus CPT-11 was well-tolerated but had minimal efficacy in children with recurrent malignant glioma and brainstem glioma.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Brain Neoplasms / drug therapy. Brain Stem Neoplasms / drug therapy. Glioma / drug therapy. Neoplasm Recurrence, Local / drug therapy
  • [MeSH-minor] Adolescent. Adult. Antibodies, Monoclonal / administration & dosage. Antibodies, Monoclonal, Humanized. Bevacizumab. Camptothecin / administration & dosage. Camptothecin / analogs & derivatives. Child. Diffusion Magnetic Resonance Imaging. Humans. Phosphorylation. Survival Rate. Treatment Outcome. Vascular Endothelial Growth Factor Receptor-2 / metabolism. Young Adult

  • Genetic Alliance. consumer health - Glioma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Childhood Brain Tumors.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Clin Cancer Res. 2007 Feb 15;13(4):1253-9 [17317837.001]
  • [Cites] Cancer Cell. 2007 Jan;11(1):83-95 [17222792.001]
  • [Cites] Nat Rev Cancer. 2008 Apr;8(4):309-16 [18337733.001]
  • [Cites] Neuro Oncol. 2008 Aug;10(4):624-30 [18539884.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2008 Oct 1;72(2):383-9 [18793954.001]
  • [Cites] Pediatr Blood Cancer. 2008 Dec;51(6):806-11 [18802947.001]
  • [Cites] Clin Cancer Res. 2008 Oct 15;14(20):6371-5 [18927275.001]
  • [Cites] J Neurooncol. 2009 Feb;91(3):329-36 [18953493.001]
  • [Cites] J Clin Oncol. 2009 Feb 10;27(5):740-5 [19114704.001]
  • [Cites] J Clin Oncol. 2009 Oct 1;27(28):4733-40 [19720927.001]
  • [Cites] Cancer Res. 2000 Apr 1;60(7):1878-86 [10766175.001]
  • [Cites] Oncogene. 2000 Nov 20;19(49):5598-605 [11114740.001]
  • [Cites] Eur J Cancer. 2001 Nov;37(16):2064-72 [11597385.001]
  • [Cites] NMR Biomed. 2002 Feb;15(1):6-17 [11840548.001]
  • [Cites] J Neurooncol. 2002 Jul;58(3):237-53 [12187958.001]
  • [Cites] J Clin Oncol. 2002 Dec 15;20(24):4684-91 [12488414.001]
  • [Cites] J Clin Oncol. 2003 Sep 15;21(18):3542; author reply 3543 [12972536.001]
  • [Cites] N Engl J Med. 1971 Nov 18;285(21):1182-6 [4938153.001]
  • [Cites] J Natl Cancer Inst. 1990 Jan 3;82(1):4-6 [1688381.001]
  • [Cites] J Clin Oncol. 1990 Jul;8(7):1277-80 [2358840.001]
  • [Cites] Cancer. 1993 Jul 1;72(1):271-5 [8508417.001]
  • [Cites] J Clin Oncol. 1999 May;17(5):1516-25 [10334539.001]
  • [Cites] J Neurooncol. 1999 May;43(1):43-7 [10448870.001]
  • [Cites] Am J Health Syst Pharm. 2004 Nov 1;61(21 Suppl 5):S21-6 [15552623.001]
  • [Cites] J Natl Cancer Inst. 2005 Feb 2;97(3):172-87 [15687360.001]
  • [Cites] Neurol Res. 2005 Jun;27(4):371-7 [15949234.001]
  • [Cites] Blood. 2005 Oct 1;106(7):2347-55 [15985545.001]
  • [Cites] Oncology. 2005;69 Suppl 3:25-33 [16301833.001]
  • [Cites] Cancer. 2006 Mar 15;106(6):1364-71 [16463390.001]
  • [Cites] Cancer Cell. 2007 Jan;11(1):69-82 [17222791.001]
  • [Cites] Cancer. 2007 Oct 1;110(7):1542-50 [17705175.001]
  • (PMID = 20479404.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Grant] United States / NCRR NIH HHS / RR / M01 RR000188; United States / NCI NIH HHS / CA / U01 CA081457; United States / NCRR NIH HHS / RR / M01RR00188; United States / NCI NIH HHS / CA / U01CA81457
  • [Publication-type] Clinical Trial, Phase II; Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Humanized; 0H43101T0J / irinotecan; 2S9ZZM9Q9V / Bevacizumab; EC 2.7.10.1 / Vascular Endothelial Growth Factor Receptor-2; XT3Z54Z28A / Camptothecin
  • [Other-IDs] NLM/ PMC2903337
  •  go-up   go-down


7. Joshi BH, Puri RA, Leland P, Varricchio F, Gupta G, Kocak M, Gilbertson RJ, Puri RK, US Pediatric Brain Tumor Consortium: Identification of interleukin-13 receptor alpha2 chain overexpression in situ in high-grade diffusely infiltrative pediatric brainstem glioma. Neuro Oncol; 2008 Jun;10(3):265-74
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Identification of interleukin-13 receptor alpha2 chain overexpression in situ in high-grade diffusely infiltrative pediatric brainstem glioma.
  • Human malignant glioma cell lines and adult brain tumors overexpress high levels of interleukin-13 receptor alpha2 chain (IL-13Ralpha2).
  • Because the IL-13Ralpha2 chain is an important target for cancer therapy and prognosis for patients with brainstem glioma (BSG) remains dismal, we investigated the expression of this receptor in specimens of diffusely infiltrative pediatric BSG relative to normal brain tissue.
  • Twenty-eight BSG specimens and 15 normal brain specimens were investigated for IL-13Ralpha2 protein expression by immunohistochemical analysis (IHC) using two different antibodies in two different laboratories.
  • By Q-dot IHC or a standard IHC assay, 17 of 28 (61%) tumor specimens showed modest to strong staining for IL-13Ralpha2, while 15 normal brain tissue samples showed weak expression for IL-13Ralpha2 protein.
  • High-level IL-13Ralpha2 RNA expression was detected in tumor samples by Q-dot ISH, but only weak RNA expression was observed in normal brain.
  • IL-13Ralpha2 protein and mRNA are expressed to significantly higher levels in BSG than in normal brain tissue.
  • Both IHC and ISH represent robust methods to detect expression of the IL-13Ralpha2 receptor in BSG that could represent an important new drug target for treatment of this disease.

  • Genetic Alliance. consumer health - Glioma.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Hum Gene Ther. 2000 Sep 1;11(13):1829-35 [10986556.001]
  • [Cites] Blood. 2000 Jun 1;95(11):3506-13 [10828036.001]
  • [Cites] Cancer Res. 2001 Aug 15;61(16):6194-200 [11507072.001]
  • [Cites] Cancer Gene Ther. 2001 Nov;8(11):861-8 [11773976.001]
  • [Cites] Cancer Res. 2002 Feb 15;62(4):1103-9 [11861389.001]
  • [Cites] Oncol Res. 2001;12(11-12):459-67 [11939409.001]
  • [Cites] Curr Treat Options Oncol. 2001 Dec;2(6):529-36 [12057098.001]
  • [Cites] J Clin Oncol. 2002 Aug 15;20(16):3431-7 [12177103.001]
  • [Cites] J Immunol. 2002 Dec 15;169(12):7119-26 [12471149.001]
  • [Cites] J Exp Med. 2003 Mar 17;197(6):703-9 [12642602.001]
  • [Cites] Clin Cancer Res. 2003 Sep 1;9(10 Pt 1):3620-4 [14506149.001]
  • [Cites] J Neurooncol. 2003 Oct;65(1):37-48 [14649884.001]
  • [Cites] Cancer. 2004 Sep 1;101(5):1036-42 [15329913.001]
  • [Cites] Mol Cell Biol. 1991 Apr;11(4):2200-5 [2005905.001]
  • [Cites] J Neurosurg. 1993 Oct;79(4):569-76 [7692018.001]
  • [Cites] Int J Cancer. 1994 Aug 15;58(4):574-81 [8056454.001]
  • [Cites] J Biol Chem. 1995 Apr 14;270(15):8797-804 [7721786.001]
  • [Cites] J Biol Chem. 1995 Jul 14;270(28):16775-80 [7622490.001]
  • [Cites] J Immunol. 1996 Apr 15;156(8):2972-8 [8609418.001]
  • [Cites] J Biol Chem. 1996 Sep 13;271(37):22428-33 [8798406.001]
  • [Cites] Pediatr Neurosurg. 1996;24(4):185-92 [8873160.001]
  • [Cites] Cancer Res. 1996 Dec 15;56(24):5631-7 [8971168.001]
  • [Cites] J Immunol. 1997 Jan 15;158(2):756-64 [8992992.001]
  • [Cites] Mol Med. 1997 May;3(5):327-38 [9205948.001]
  • [Cites] Cancer Res. 1997 Aug 1;57(15):3272-80 [9242460.001]
  • [Cites] J Biol Chem. 1997 Aug 8;272(32):20251-8 [9242704.001]
  • [Cites] J Urol. 1997 Sep;158(3 Pt 1):948-53 [9258124.001]
  • [Cites] Biochem Biophys Res Commun. 1997 Sep 8;238(1):90-4 [9299458.001]
  • [Cites] Nat Med. 1997 Dec;3(12):1362-8 [9396606.001]
  • [Cites] Int Immunol. 1998 Aug;10(8):1103-10 [9723696.001]
  • [Cites] J Natl Cancer Inst. 1998 Sep 2;90(17):1269-77 [9731733.001]
  • [Cites] Clin Cancer Res. 1995 Nov;1(11):1253-8 [9815919.001]
  • [Cites] Clin Cancer Res. 1997 Feb;3(2):151-6 [9815666.001]
  • [Cites] Int J Mol Med. 1998 Mar;1(3):551-7 [9852261.001]
  • [Cites] Biophys J. 1999 Jul;77(1):154-72 [10388747.001]
  • [Cites] Cancer Res. 2005 Apr 1;65(7):2956-63 [15805299.001]
  • [Cites] Nat Med. 2006 Jan;12(1):99-106 [16327802.001]
  • [Cites] Technol Cancer Res Treat. 2006 Jun;5(3):239-50 [16700620.001]
  • [Cites] Clin Cancer Res. 2006 May 15;12(10):3145-51 [16707614.001]
  • [Cites] Vitam Horm. 2006;74:479-504 [17027527.001]
  • [Cites] J Clin Oncol. 2007 Mar 1;25(7):837-44 [17327604.001]
  • [Cites] Int J Hematol. 1999 Jan;69(1):13-20 [10641437.001]
  • [Cites] Cancer Res. 2000 Mar 1;60(5):1168-72 [10728667.001]
  • [Cites] Int J Cancer. 2001 Apr 15;92(2):168-75 [11291041.001]
  • (PMID = 18430795.001).
  • [ISSN] 1522-8517
  • [Journal-full-title] Neuro-oncology
  • [ISO-abbreviation] Neuro-oncology
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / U01 CA081457; United States / NCI NIH HHS / CA / U01 CA81457
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Interleukin-13 Receptor alpha2 Subunit; 0 / RNA, Messenger
  • [Other-IDs] NLM/ PMC2563049
  •  go-up   go-down


8. Riina HA, Knopman J, Greenfield JP, Fralin S, Gobin YP, Tsiouris AJ, Souweidane MM, Boockvar JA: Balloon-assisted superselective intra-arterial cerebral infusion of bevacizumab for malignant brainstem glioma. A technical note. Interv Neuroradiol; 2010 Mar;16(1):71-6
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Balloon-assisted superselective intra-arterial cerebral infusion of bevacizumab for malignant brainstem glioma. A technical note.
  • Malignant brainstem gliomas (BSG) are rare tumors in adults, associated with a grim prognosis and limited treatment options.
  • Currently, radiotherapy represents the mainstay of treatment, although new studies suggest an increased role for certain chemotherapeutic agents.
  • Intravenous (IV) administration of bevacizumab (Avastin, Genentech Pharmaceuticals) has been shown to be active in the treatment of some enhancing malignant brainstem gliomas.
  • The IV route of administration, however, carries a risk of systemic side effects such as bowel perforation, wound disrepair and pulmonary embolism.
  • In addition, the percentage of IV drug that reaches the tumor site is restricted by the blood brain barrier (BBB).Weill Cornell Brain Tumor Center, Department of Neurosurgery, Weill Cornell Medical College of Cornell University: New York, NY, USA.
  • This technical report describes our protocol in performing superselective intra-arterial cerebral infusion (SIACI) of bevacizumab using endovascular balloon-assistance in the top of the basilar artery in a patient with a recurrent malignant brainstem glioma.
  • This method of drug delivery may have important implications in the treatment of both adult and pediatric brainstem gliomas.
  • [MeSH-major] Antibodies, Monoclonal / administration & dosage. Brain Stem Neoplasms / diagnostic imaging. Brain Stem Neoplasms / drug therapy. Catheterization / methods. Glioma / diagnostic imaging. Glioma / drug therapy. Infusions, Intra-Arterial / methods
  • [MeSH-minor] Adult. Antibodies, Monoclonal, Humanized. Antineoplastic Agents / administration & dosage. Bevacizumab. Humans. Male. Radiography. Treatment Outcome

  • Genetic Alliance. consumer health - Glioma.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Radiology. 2001 Mar;218(3):724-32 [11230646.001]
  • [Cites] J Exp Ther Oncol. 2009;8(2):145-50 [20192120.001]
  • [Cites] Neurosurgery. 1985 Sep;17(3):419-23 [3930991.001]
  • [Cites] Neurosurgery. 1986 Oct;19(4):573-82 [3097567.001]
  • [Cites] J Neurooncol. 1987;4(3):195-207 [3104548.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1998 Jan 15;40(2):265-71 [9457808.001]
  • [Cites] J Neurooncol. 1998 Nov;40(2):171-7 [9892099.001]
  • [Cites] Arch Neurol. 1999 Apr;56(4):421-5 [10199329.001]
  • [Cites] Neurology. 2006 Apr 25;66(8):1258-60 [16636248.001]
  • [Cites] J Neurooncol. 2006 May;77(3):279-84 [16314949.001]
  • [Cites] Pediatr Blood Cancer. 2006 Aug;47(2):174-82 [16086410.001]
  • [Cites] Clin Cancer Res. 2007 Feb 15;13(4):1253-9 [17317837.001]
  • [Cites] J Clin Oncol. 2007 Oct 20;25(30):4714-21 [17947718.001]
  • [Cites] J Neurol. 2008 Feb;255(2):171-7 [18293027.001]
  • [Cites] J Neurooncol. 2008 Jul;88(3):339-47 [18389177.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2008 Aug 1;71(5):1372-80 [18355978.001]
  • [Cites] Neuro Oncol. 2008 Jun;10(3):355-60 [18436627.001]
  • [Cites] J Clin Oncol. 2009 Oct 1;27(28):4733-40 [19720927.001]
  • [Cites] Brain. 2001 Dec;124(Pt 12):2528-39 [11701605.001]
  • (PMID = 20377982.001).
  • [ISSN] 1591-0199
  • [Journal-full-title] Interventional neuroradiology : journal of peritherapeutic neuroradiology, surgical procedures and related neurosciences
  • [ISO-abbreviation] Interv Neuroradiol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Humanized; 0 / Antineoplastic Agents; 2S9ZZM9Q9V / Bevacizumab
  • [Other-IDs] NLM/ PMC3277958
  •  go-up   go-down


9. Thomale UW, Tyler B, Renard V, Dorfman B, Chacko VP, Carson BS, Haberl EJ, Jallo GI: Neurological grading, survival, MR imaging, and histological evaluation in the rat brainstem glioma model. Childs Nerv Syst; 2009 Apr;25(4):433-41
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Neurological grading, survival, MR imaging, and histological evaluation in the rat brainstem glioma model.
  • OBJECTIVE: Convection-enhanced delivery using carboplatin in brainstem glioma models was reported to prolong survival.
  • We established a neurological scoring system for the rat brainstem glioma model.
  • In 38 animals survival time was recorded.
  • HE staining was used to evaluate tumor extension.
  • Survival was significantly prolonged compared to control animals in the high dose carboplatin-one cannula group as well as in both low dose carboplatin groups (18.6 +/- 3 versus 26.3 +/- 9, 22.8 +/- 2, 23.6 +/- 2 days; p < 0.05).
  • MR imaging showed a focal contrast enhancing mass in the pontine brainstem, which was less exaggerated after local chemotherapy.
  • Histological slices visualized decreased cellular density in treatment animals versus controls.
  • CONCLUSION: Local chemotherapy in the brainstem glioma model showed significant efficacy for histological changes and survival.
  • Our neurological grading enables quantification of drug and tumor-related morbidity as an important factor for functional performance during therapy.
  • [MeSH-major] Brain Stem Neoplasms / pathology. Glioma / pathology
  • [MeSH-minor] Animals. Antineoplastic Agents / therapeutic use. Body Weight. Carboplatin / therapeutic use. Catheterization. Cell Line, Tumor. Disease Models, Animal. Dose-Response Relationship, Drug. Kaplan-Meier Estimate. Magnetic Resonance Imaging. Male. Neoplasm Staging. Random Allocation. Rats. Rats, Inbred F344. Severity of Illness Index

  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. CARBOPLATIN .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Neurooncol. 2004 May;67(3):327-34 [15164988.001]
  • [Cites] J Neurooncol. 2004 May;67(3):319-26 [15164987.001]
  • [Cites] Ann Surg Oncol. 2008 Oct;15(10):2887-93 [18636295.001]
  • [Cites] Childs Nerv Syst. 2006 Jan;22(1):1-2 [16311768.001]
  • [Cites] Eur J Nucl Med Mol Imaging. 2005 Sep;32(9):1018-25 [15877226.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1988 Aug;15(2):311-8 [2841262.001]
  • [Cites] Bone Marrow Transplant. 1996 Jul;18(1):143-9 [8832007.001]
  • [Cites] J Neurosurg. 2004 Mar;100(3):472-9 [15035283.001]
  • [Cites] J Neurooncol. 2006 Sep;79(3):281-7 [16598416.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1993 Sep 30;27(2):197-206 [8407392.001]
  • [Cites] J Natl Cancer Inst. 1979 Apr;62(4):811-7 [219282.001]
  • [Cites] Neuro Oncol. 2008 Apr;10(2):112-20 [18287341.001]
  • [Cites] Brain Res. 2000 Apr 28;863(1-2):94-105 [10773197.001]
  • [Cites] J Neurosurg. 2003 Nov;99(5):893-8 [14609170.001]
  • [Cites] Clin Cancer Res. 2006 May 15;12(10):3145-51 [16707614.001]
  • [Cites] J Neurosurg. 2002 May;96(5):885-91 [12005396.001]
  • [Cites] Childs Nerv Syst. 2006 Dec;22(12):1519-25 [17021732.001]
  • [Cites] J Neurooncol. 2002 Nov;60(2):151-8 [12635662.001]
  • [Cites] Neurosurgery. 2003 Jun;52(6):1411-22; discussion 1422-4 [12762886.001]
  • [Cites] Acta Neurochir Suppl. 2003;88:105-11 [14531568.001]
  • [Cites] J Neurooncol. 1988 Dec;6(4):309-17 [3221258.001]
  • [Cites] Stroke. 1986 May-Jun;17(3):472-6 [3715945.001]
  • [Cites] Acta Neurochir (Wien). 2006 Mar;148(3):269-75; discussion 275 [16482400.001]
  • [Cites] Cancer. 2005 Dec 15;104(12):2792-7 [16265674.001]
  • [Cites] Surg Technol Int. 2006;15:311-6 [17029190.001]
  • [Cites] Clin Cancer Res. 2007 Sep 1;13(17):5195-201 [17726137.001]
  • [Cites] Expert Rev Anticancer Ther. 2007 Dec;7(12 Suppl):S79-85 [18076322.001]
  • [Cites] Cancer Chemother Pharmacol. 2007 Oct;60(5):643-50 [17256133.001]
  • [Cites] Neurosurgery. 2007 Nov;61(5):1031-7; discussion 1037-8 [18091279.001]
  • [Cites] J Neurooncol. 1998 Jan;36(1):91-102 [9525831.001]
  • [Cites] J Neurooncol. 2006 May;77(3):279-84 [16314949.001]
  • [Cites] J Neurosurg. 2007 Jul;107(1):190-7 [17639894.001]
  • [Cites] Arch Dis Child. 1999 Jun;80(6):558-64 [10332008.001]
  • [Cites] Childs Nerv Syst. 2009 Jan;25(1):21-8 [18690465.001]
  • (PMID = 19082613.001).
  • [ISSN] 1433-0350
  • [Journal-full-title] Child's nervous system : ChNS : official journal of the International Society for Pediatric Neurosurgery
  • [ISO-abbreviation] Childs Nerv Syst
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Antineoplastic Agents; BG3F62OND5 / Carboplatin
  •  go-up   go-down


10. Warren K, Jakacki R, Widemann B, Aikin A, Libucha M, Packer R, Vezina G, Reaman G, Shaw D, Krailo M, Osborne C, Cehelsky J, Caldwell D, Stanwood J, Steinberg SM, Balis FM: Phase II trial of intravenous lobradimil and carboplatin in childhood brain tumors: a report from the Children's Oncology Group. Cancer Chemother Pharmacol; 2006 Sep;58(3):343-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phase II trial of intravenous lobradimil and carboplatin in childhood brain tumors: a report from the Children's Oncology Group.
  • BACKGROUND: [corrected] Lobradimil is a synthetic bradykinin analog that rapidly and transiently increases the permeability of the blood-brain barrier (BBB).
  • The combination of lobradimil and carboplatin was studied in pediatric patients with primary brain tumors in a phase II trial, the primary endpoints of which were to estimate the response rate and time to disease progression.
  • PATIENTS AND METHODS: Patients were stratified by histology into five cohorts: brainstem glioma, high-grade glioma, low-grade glioma, medullobastoma/primitive neuroectodermal tumor (PNET), and ependymoma.
  • No objective responses were observed in the brainstem glioma (n=12) and high-grade glioma (n = 9) cohorts, although two patients with high-grade glioma had prolonged disease stabilization (>6 months).
  • The study was closed for commercial reasons prior to achieving the accrual goals for the ependymoma (n = 8), medulloblastoma/PNET (n = 6) and low-grade glioma (n = 2) cohorts, although responses were observed in 1 patient with PNET and 2 patients with ependymoma.
  • CONCLUSION: The combination of lobradimil and carboplatin was inactive in childhood high-grade gliomas and brainstem gliomas.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Blood-Brain Barrier / metabolism. Brain Neoplasms / drug therapy
  • [MeSH-minor] Adolescent. Adult. Bradykinin / administration & dosage. Bradykinin / adverse effects. Bradykinin / analogs & derivatives. Bradykinin / therapeutic use. Carboplatin / administration & dosage. Carboplatin / adverse effects. Carboplatin / therapeutic use. Child. Child, Preschool. Cohort Studies. Drug Administration Schedule. Humans. Infusions, Intravenous. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Childhood Brain Tumors.
  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • Hazardous Substances Data Bank. CARBOPLATIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16408203.001).
  • [ISSN] 0344-5704
  • [Journal-full-title] Cancer chemotherapy and pharmacology
  • [ISO-abbreviation] Cancer Chemother. Pharmacol.
  • [Language] eng
  • [Grant] United States / Intramural NIH HHS / /
  • [Publication-type] Clinical Trial, Phase II; Journal Article; Research Support, N.I.H., Intramural; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  • [Chemical-registry-number] 159768-75-9 / RMP 7; BG3F62OND5 / Carboplatin; S8TIM42R2W / Bradykinin
  •  go-up   go-down


11. Becher OJ, Hambardzumyan D, Walker TR, Helmy K, Nazarian J, Albrecht S, Hiner RL, Gall S, Huse JT, Jabado N, MacDonald TJ, Holland EC: Preclinical evaluation of radiation and perifosine in a genetically and histologically accurate model of brainstem glioma. Cancer Res; 2010 Mar 15;70(6):2548-57
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Preclinical evaluation of radiation and perifosine in a genetically and histologically accurate model of brainstem glioma.
  • Brainstem gliomas (BSG) are a rare group of central nervous system tumors that arise mostly in children and usually portend a particularly poor prognosis.
  • We report the development of a genetically engineered mouse model of BSG using the RCAS/tv-a system and its implementation in preclinical trials.
  • Using immunohistochemistry, we found that platelet-derived growth factor (PDGF) receptor alpha is overexpressed in 67% of pediatric BSGs.
  • To generate high-grade BSGs, we overexpressed PDGF-B in combination with Ink4a-ARF loss, given that this locus is commonly lost in high-grade pediatric BSGs.
  • This PDGF-induced BSG model can serve as a preclinical tool for the testing of novel agents.
  • [MeSH-major] Brain Stem Neoplasms / drug therapy. Brain Stem Neoplasms / radiotherapy. Disease Models, Animal. Glioma / drug therapy. Glioma / radiotherapy. Phosphorylcholine / analogs & derivatives
  • [MeSH-minor] Animals. Combined Modality Therapy. Genetic Engineering. Inbreeding. Mice. Mice, Inbred BALB C. Receptor, Platelet-Derived Growth Factor alpha / biosynthesis

  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • KOMP Repository. gene/protein/disease-specific - KOMP Repository (subscription/membership/fee required).
  • Mouse Genome Informatics (MGI). Mouse Genome Informatics (MGI) .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • antibodies-online. View related products from antibodies-online.com (subscription/membership/fee required).
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Neuropathol Exp Neurol. 1997 Jul;56(7):782-9 [9210874.001]
  • [Cites] Acta Neuropathol. 1996 Jul;92(1):90-7 [8811130.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1999 Mar 15;43(5):959-64 [10192340.001]
  • [Cites] Indian J Cancer. 2004 Oct-Dec;41(4):170-4 [15659871.001]
  • [Cites] Cancer Res. 2005 Aug 15;65(16):7429-35 [16103096.001]
  • [Cites] Lancet Oncol. 2006 Mar;7(3):241-8 [16510333.001]
  • [Cites] Cancer Cell. 2006 May;9(5):391-403 [16697959.001]
  • [Cites] Cancer Res. 2006 Dec 1;66(23):11172-8 [17145861.001]
  • [Cites] Childs Nerv Syst. 2006 Dec;22(12):1519-25 [17021732.001]
  • [Cites] J Neurosurg. 2007 Jul;107(1 Suppl):1-4 [17647306.001]
  • [Cites] Genes Dev. 2008 Feb 15;22(4):436-48 [18281460.001]
  • [Cites] J Neurooncol. 2008 May;87(3):247-53 [18193393.001]
  • [Cites] Clin Cancer Res. 2008 Jun 1;14(11):3386-94 [18519768.001]
  • [Cites] Cancer. 2008 Aug 1;113(3):566-72 [18484645.001]
  • [Cites] J Neurosurg. 2008 Nov;109(5):849-55 [18976074.001]
  • [Cites] Br J Neurosurg. 2008 Oct;22(5):619-24 [19016112.001]
  • [Cites] Mol Cancer Res. 2006 Dec;4(12):927-34 [17189383.001]
  • [Cites] Neuro Oncol. 2007 Apr;9(2):113-23 [17327574.001]
  • [Cites] J Clin Oncol. 2007 Apr 1;25(10):1196-208 [17401009.001]
  • [Cites] Stem Cells. 2008 Dec;26(12):3027-36 [18802038.001]
  • [Cites] Cancer Cell. 2009 Jan 6;15(1):45-56 [19111880.001]
  • [Cites] Neurosurgery. 2009 Mar;64(3):455-61; discussion 461-2 [19240607.001]
  • [Cites] Eur J Cancer. 2009 Sep;45(13):2342-51 [19362466.001]
  • [Cites] J Neurooncol. 2010 Jan;96(2):151-9 [19585223.001]
  • [Cites] Hum Pathol. 1999 Nov;30(11):1284-90 [10571506.001]
  • [Cites] Brain Pathol. 2000 Apr;10(2):249-59 [10764044.001]
  • [Cites] Nat Genet. 2000 May;25(1):55-7 [10802656.001]
  • [Cites] Genes Dev. 2001 Aug 1;15(15):1913-25 [11485986.001]
  • [Cites] Brain. 2001 Dec;124(Pt 12):2528-39 [11701605.001]
  • [Cites] J Neurooncol. 2002 Sep;59(2):117-22 [12241104.001]
  • [Cites] Neurol Med Chir (Tokyo). 2003 Aug;43(8):375-82; discussion 382 [12968803.001]
  • [Cites] Clin Cancer Res. 2003 Sep 1;9(10 Pt 1):3620-4 [14506149.001]
  • [Cites] J Neuropathol Exp Neurol. 1993 Sep;52(5):507-15 [8103086.001]
  • [Cites] Biochem Biophys Res Commun. 1993 Oct 29;196(2):851-7 [8240361.001]
  • [Cites] Neurosurgery. 1993 Dec;33(6):1026-9; discussion 1029-30 [8133987.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1998 Jan 15;40(2):265-71 [9457808.001]
  • (PMID = 20197468.001).
  • [ISSN] 1538-7445
  • [Journal-full-title] Cancer research
  • [ISO-abbreviation] Cancer Res.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / R01 CA100688; United States / NCI NIH HHS / CA / R01 CA100688; United States / NCI NIH HHS / CA / U01 CA141502; United States / NCI NIH HHS / CA / U01 CA141502; United States / NCI NIH HHS / CA / U54 CA126518; United States / NCI NIH HHS / CA / U54 CA126518
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 107-73-3 / Phosphorylcholine; 2GWV496552 / perifosine; EC 2.7.10.1 / Receptor, Platelet-Derived Growth Factor alpha
  • [Other-IDs] NLM/ NIHMS171774; NLM/ PMC3831613
  •  go-up   go-down


12. Siu IM, Tyler BM, Chen JX, Eberhart CG, Thomale UW, Olivi A, Jallo GI, Riggins GJ, Gallia GL: Establishment of a human glioblastoma stemlike brainstem rodent tumor model. J Neurosurg Pediatr; 2010 Jul;6(1):92-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Establishment of a human glioblastoma stemlike brainstem rodent tumor model.
  • OBJECT: Diffuse brainstem tumors are the most difficult type of pediatric CNS malignancy to treat.
  • It is therefore essential to develop a reliable animal model to screen new therapeutic agents for the treatment of this type of tumor.
  • Ten female Fischer 344 rats received an injection of 75,000 F98 rat glioma cells and 10 female athymic nude rats received an injection of 75,000 060919 human glioblastoma stemlike cells in the pontine tegmentum of the brainstem.
  • A control group of 5 female Fischer rats received an injection of saline in the same location as the animals in the tumor groups.
  • RESULTS: Both F98 cells and 060919 cells grew in 100% of the animals injected.
  • Median survival of animals injected with F98 was 15 days, consistent with the authors' previous reports on the establishment of the brainstem tumor model using the F98 rat glioma line.
  • Median survival of animals injected with 060919 was 31 days.
  • Histopathological analysis of the tumors confirmed the presence of brainstem lesions in animals that received brainstem injections of F98 and in animals that received brainstem injections of 060919.
  • The 060919 brainstem tumors histologically resembled glioblastoma.
  • CONCLUSIONS: Tumor take and median survival were consistent for animals injected in the brainstem with either the established F98 rat glioma cell line or the 060919 human glioblastoma stemlike neurosphere line.
  • Histopathological features of the 060919 brainstem tumors resembled glioblastoma.
  • Establishment of this human glioblastoma stemlike brainstem animal model will improve the evaluation and identification of more efficacious agents for the treatment of high-grade brainstem tumors.
  • [MeSH-major] Brain Stem Neoplasms / pathology. Disease Models, Animal. Glioblastoma / pathology. Multipotent Stem Cells / pathology. Neoplastic Stem Cells / pathology
  • [MeSH-minor] Animals. Brain Stem / pathology. Cell Line, Tumor. Child. Female. Glioma / pathology. Humans. Mice. Mice, Nude. Neoplasm Transplantation. Rats. Rats, Inbred F344. Rats, Nude. Spheroids, Cellular / pathology

  • Genetic Alliance. consumer health - Glioblastoma.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20593994.001).
  • [ISSN] 1933-0715
  • [Journal-full-title] Journal of neurosurgery. Pediatrics
  • [ISO-abbreviation] J Neurosurg Pediatr
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


13. Warren KE, Frank JA, Black JL, Hill RS, Duyn JH, Aikin AA, Lewis BK, Adamson PC, Balis FM: Proton magnetic resonance spectroscopic imaging in children with recurrent primary brain tumors. J Clin Oncol; 2000 Mar;18(5):1020-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Proton magnetic resonance spectroscopic imaging in children with recurrent primary brain tumors.
  • We measured the relative tumor concentrations of these biochemical markers in children with recurrent brain tumors and evaluated their potential prognostic significance.
  • PATIENTS AND METHODS: (1)H-MRSI was performed on 27 children with recurrent primary brain tumors referred to our institution for investigational drug trials.
  • Diagnoses included high-grade glioma (n = 10), brainstem glioma (n = 7), medulloblastoma/peripheral neuroectodermal tumor (n = 6), ependymoma (n = 3), and pineal germinoma (n = 1). (1)H-MRSI was performed on 1.
  • The concentrations of choline (Cho) and N-acetyl-aspartate (NAA) in the tumor and normal brain were quantified using a multislice multivoxel method, and the maximum Cho:NAA ratio was determined for each patient's tumor.
  • RESULTS: The maximum Cho:NAA ratio ranged from 1.1 to 13.2 (median, 4.5); the Cho:NAA ratio in areas of normal-appearing brain tissue was less than 1.0.
  • The maximum Cho:NAA ratio for each histologic subtype varied considerably; approximately equal numbers of patients within each tumor type had maximum Cho:NAA ratios above and below the median.
  • CONCLUSION: The maximum tumor Cho:NAA ratio seems to be predictive of outcome in children with recurrent primary brain tumors and should be evaluated as a prognostic indicator in newly diagnosed childhood brain tumors.
  • [MeSH-major] Brain Neoplasms / diagnosis. Magnetic Resonance Spectroscopy / methods
  • [MeSH-minor] Adolescent. Adult. Biomarkers, Tumor / analysis. Child. Child, Preschool. Humans. Neoplasm Recurrence, Local. Pilot Projects. Prognosis. Protons

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Childhood Brain Tumors.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 10694552.001).
  • [ISSN] 0732-183X
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Protons
  •  go-up   go-down


14. Ronghe M, Hargrave D, Bartels U, Tabori U, Vaidya S, Chandler C, Kulkarni A, Bouffet E: Vincristine and carboplatin chemotherapy for unresectable and/or recurrent low-grade astrocytoma of the brainstem. Pediatr Blood Cancer; 2010 Sep;55(3):471-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Vincristine and carboplatin chemotherapy for unresectable and/or recurrent low-grade astrocytoma of the brainstem.
  • BACKGROUND: Radiotherapy remains a widely accepted postoperative treatment modality for unresectable or recurrent low-grade glioma (LGG).
  • The majority of the published experience is in children with hypothalamic/optic chiasmatic lesions and little information is available regarding its use in LGG of the brainstem.
  • PROCEDURE: We describe clinical characteristics and course of children with LGG of the brainstem who received carboplatin-based chemotherapy in two institutions over 10 years (1996-2006).
  • This was a retrospective review of consecutively treated children with LGG of the brainstem (midbrain, pons, medulla, and upper cervical cord).
  • CONCLUSIONS: The efficacy of this chemotherapy regimen in this series supports its role in children with progressive unresectable LGG of brainstem.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Astrocytoma / drug therapy. Brain Stem. Brain Stem Neoplasms / drug therapy
  • [MeSH-minor] Carboplatin / administration & dosage. Child. Child, Preschool. Disease Progression. Female. Humans. Infant. Male. Neoplasm Recurrence, Local / drug therapy. Vincristine / administration & dosage

  • Hazardous Substances Data Bank. CARBOPLATIN .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] 2010 Wiley-Liss, Inc.
  • (PMID = 20535831.001).
  • [ISSN] 1545-5017
  • [Journal-full-title] Pediatric blood & cancer
  • [ISO-abbreviation] Pediatr Blood Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 5J49Q6B70F / Vincristine; BG3F62OND5 / Carboplatin
  •  go-up   go-down


15. Hayward RM, Patronas N, Baker EH, Vézina G, Albert PS, Warren KE: Inter-observer variability in the measurement of diffuse intrinsic pontine gliomas. J Neurooncol; 2008 Oct;90(1):57-61
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Diffuse intrinsic pontine glioma (DIPG) is an invasive pediatric brainstem tumor with a poor prognosis.
  • Patients commonly enter investigational trials, many of which use radiographic response as an endpoint for assessing drug efficacy.
  • Results confirmed that there is wide variability in DIPG tumor measurements between readers for all image types.
  • [MeSH-major] Brain Stem Neoplasms / epidemiology. Brain Stem Neoplasms / pathology. Glioma / epidemiology. Glioma / pathology. Magnetic Resonance Imaging
  • [MeSH-minor] Child. Child, Preschool. Clinical Trials, Phase II as Topic. Female. Humans. Infant. Male. Observer Variation

  • MedlinePlus Health Information. consumer health - MRI Scans.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Natl Cancer Inst. 2000 Feb 2;92(3):205-16 [10655437.001]
  • [Cites] Radiology. 2001 Feb;218(2):586-91 [11161183.001]
  • [Cites] J Natl Cancer Inst. 2001 Sep 19;93(18):1401-5 [11562391.001]
  • [Cites] Cancer. 1981 Jan 1;47(1):207-14 [7459811.001]
  • [Cites] AJNR Am J Neuroradiol. 2008 Mar;29(3):419-24 [18272557.001]
  • [Cites] J Natl Cancer Inst. 1998 Sep 2;90(17):1269-77 [9731733.001]
  • [Cites] J Neurooncol. 2005 Dec;75(3):253-66 [16195805.001]
  • [Cites] Lancet Oncol. 2006 Mar;7(3):241-8 [16510333.001]
  • [Cites] Eur J Cancer. 2006 May;42(8):1031-9 [16616487.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1998 Jan 15;40(2):265-71 [9457808.001]
  • (PMID = 18587536.001).
  • [ISSN] 0167-594X
  • [Journal-full-title] Journal of neuro-oncology
  • [ISO-abbreviation] J. Neurooncol.
  • [Language] eng
  • [Grant] United States / Intramural NIH HHS / / Z01 BC010580-04; United States / Intramural NIH HHS / / Z01 BC010589-04
  • [Publication-type] Journal Article; Research Support, N.I.H., Intramural
  • [Publication-country] Netherlands
  • [Other-IDs] NLM/ NIHMS65973; NLM/ PMC2600617
  •  go-up   go-down






Advertisement